The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer.

Saved in:
Bibliographic Details
Title: The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer.
Authors: Cecchini M; Department of Internal Medicine, Medical Oncology, Yale University School of Medicine, New Haven, Connecticut., Han SW; Department of Internal Medicine, Seoul National University Hospital and Seoul National University Cancer Research Institute, Seoul, South Korea., Lee S; Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul, South Korea., Lee KW; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea., Kopetz S; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Mizrahi J; Department of Medical Oncology, Ochsner Medical Center, New Orleans, Louisiana., Hong YS; Department of Oncology, Asan Medical Center, Seoul, South Korea., Ghiringhelli F; Department of Medical Oncology, Centre Georges Francois Leclerc, Dijon, France., Italiano A; Department of Medicine, Institut Bergonie, Bordeaux, France.; Faculty of Medicine, University of Bordeaux, Bordeaux, France., Tougeron D; Department of Gastroenterology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France., Beagle B; Arcus Biosciences, Inc., Hayward, California., Boakye M; Arcus Biosciences, Inc., Hayward, California., Zhao T; Arcus Biosciences, Inc., Hayward, California., Khemka V; Arcus Biosciences, Inc., Hayward, California., Wainberg ZA; Department of Gastrointestinal Medical Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 Jul 01; Vol. 32 (13), pp. 2593-2603.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-25-3727